PRNewswire

MINNEAPOLIS, May 10, 2024 /PRNewswire/ -- Ally Law, a prestigious global network with 80 law firm members in 50 countries, is proud to announce its 2024–2025 Executive Board, elected by members on May 7 and 8, 2024.

Ally Law's new Treasurer is James Turner (McVeah Fleming; Auckland, New Zealand), a skilled lawyer with a focus on helping businesses and individuals resolve disputes and navigate their legal obligations. Prior to taking on his new responsibilities, Mr.... (continue reading...)

Jury finds systemic wage violations for more than 33,000 hourly employees in Washington state based on unlawful timeclock rounding and second meal period violations.

SEATTLE, May 10, 2024 /PRNewswire/ -- The judgment in Bennett, et. al v. Providence Health & Services, was entered in King County Superior Court yesterday, the culmination of a two-week trial which took place late last month. Providence is ordered to pay more than 33,000 of its hourly employees more than... (continue reading...)

MANCHESTER, England, May 9, 2024 /PRNewswire/ -- UK-headquartered, global Identity and Access Management (IAM) specialist, ProofID has won the Judge's Award for Global Ambition at the Northern Tech Awards held at Manchester Cathedral. The company won the award in recognition of its expansion in the USA following the successful acquisitions of Regatta Solutions an Austin, Texas based Identity Governance and Administration (IGA) integrator and PEGRight a Colorado... (continue reading...)

NEW YORK, May 10, 2024 /PRNewswire/ -- Sphere Entertainment Co. (NYSE: SPHR) ("Sphere Entertainment" or the "Company") today reported financial results for the fiscal third quarter ended March 31, 2024.

Recent Sphere highlights include:

• The conclusion of U2's sold-out 40-show run in March and Phish's sold-out 4-night run in April;
• Dead & Co.'s... (continue reading...)

PRINCETON, N.J., May 10, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended March 31, 2024.